Table 1.
Subject Group | Age at Initial Scan Date | Age at First Treatmenta | Duration of Illnessb | PANSSc | MMSEd | ||
---|---|---|---|---|---|---|---|
Positive | Negative | General | |||||
FULL BASELINE SAMPLE (n=145) | |||||||
Healthy Subjects (n=41) | 44.15±14.66 | 29.86±9.12 | |||||
Schizophrenia Patients (n=104) | 42.77±12.12 | 24.96±9.12 | 18.49±12.71 | 18.86±6.64 | 18.91±7.77 | 37.07±9.87 | 26.86±2.71 |
Good-Outcome Patients (n=51) | 40.62±12.60 | 26.82±7.06 | 14.82±12.10 | 16.04±4.94 | 16.25±5.53 | 32.38±7.83 | 27.00±2.64 |
Poor-Outcome Patients (n=53) | 44.79±11.39 | 22.82±10.74 | 22.74±12.20 | 21.74±6.94 | 21.60±8.72 | 41.81±9.42 | 26.72±2.80 |
FOLLOW-UP COHORT (n=65) | |||||||
Healthy Subjects (n=16) | 41.62±12.23 | 30.00±0.00 | |||||
Schizophrenia Patients (n=49) | 42.69±12.29 | 23.80±8.01 | 18.67±12.05 | 19.04±6.80 | 19.00±7.25 | 40.53±13.23 | 26.47±3.15 |
Good-Outcome Patients (n=23) | 37.44±10.68 | 26.81±5.51 | 12.29±8.78 | 15.39±4.92 | 15.35±5.08 | 35.32±14.63 | 27.32±2.36 |
Poor-Outcome Patients (n=26) | 47.35±11.90 | 20.96±9.05 | 24.77±11.71 | 22.4±6.64 | 22.36±7.40 | 45.12±10.05 | 25.79±3.56 |
DROP-OUT SAMPLE (n=80) | |||||||
Healthy Subjects (n=25) | 45.62±15.75 | 29.77±0.53 | |||||
Schizophrenia Patients (n=55) | 43.19±12.37 | 25.38±9.88 | 18.40±13.08 | 18.38±6.20 | 19.00±8.46 | 35.52±10.14 | 27.20±2.43 |
Good-Outcome Patients (n=28) | 42.21±13.25 | 26.46±8.10 | 16.54±13.66 | 16.96±5.53 | 16.52±5.98 | 33.27±7.83 | 27.36±2.08 |
Poor-Outcome Patients (n=27) | 43.62±11.53 | 23.90±11.98 | 20.95±12.12 | 20.36±6.63 | 21.23±9.87 | 40.04±8.86 | 27.35±2.41 |
Documented age at the time of first exposure to antipsychotic agents.
Time (in years) since the first illness-related exposure to antipsychotic agents to the initial scan.
Positive and Negative Syndrome Scale.
Mini-Mental State Examination.